3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Uterine Cervical Neoplasms
1
Neurotoxicity Syndromes
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Cytokine Release Syndrome
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Paclitaxel
5
Vincristine
3
Oxaliplatin
3
Mental Status and Dementia Tests
3
Magnetic Resonance Spectroscopy
3
Carboplatin
3
Amifostine
3
xaliproden
2
glucarpidase
2
Taxes
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Procarbazine
2
Methotrexate
2
Magnesium Sulfate
2
Leucovorin
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
Calcium Gluconate
2
2,2'-dithiodiethanesulfonic acid
2
neurotropin
1
glutamic acid diethyl ester
1
eribulin
1
axicabtagene ciloleucel
1
Vitamin E
1
Trastuzumab
1
Thioctic Acid
1
Thalidomide
1
Tadalafil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neurotoxicity Syndromes
×
Contrast Media
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled